Treating Hypertension Using Erythropoietin and its Derivatives


Erythropoietin (EPO), a natural hormone produced by kidneys is associated with stimulation of red blood cell production. Recombinant human erythropoietin (rhEPO) is currently used for treatment of anemia and has powerful cardioprotective properties. Hypertension remains a major health problem and a serious risk factor for stroke and chronic heart failure. Researchers at the NIH have discovered that administering a therapeutically effective dose of rhEPO or an EPO derivative including carbamylated erythropoietin (CEPO) and Helix B surface peptide (HBSP), have an acutely reducing both systolic and diastolic blood pressure, via Nitric Oxide (NO) signaling. Long-term administration of derivative of EPO, HBSP, prevents elevation of arterial blood pressure in an animal model of hypertension. Unlike long-term treatment with rhEPO, administration of EPO derivatives, such as HBSP, does not stimulate excessive red cell production and will be useful in the development of anti-hypertensive drugs.



Potential Commercial Applications: Competitive Advantages:
  • Potential therapeutic for the treatment of hypertension
 
  • Administration of EPO and its derivatives does not stimulate excessive red blood cell production
  • Technology utilizes activation of natural vasodilatation mechanisms
  • rhEPO and EPO derivatives provide tissue-protective properties, which none of existing antihypertensive drugs do


Development Stage:
Discovery (Lead Identification)

Inventors:

Mark Talan (NCI)  ➽ more inventions...


Intellectual Property:
U.S. Provisional Application No. 61/636,547
U.S. Provisional Application No. 61/638,328
U.S. Provisional Application No. 61/656,698
Foreign Filed Application No. PCT/US2013/03715

Publications:
Ahmet I, et al. Acute hemodynamic effects of erythropoietin do not mediate its cardioprotective properties.  PMID 23213383

Collaboration Opportunity:

Licensing only


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-158-2012
Updated: Mar 9, 2018